News

Cara Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KORSUVA™ Injection in Hemodialysis Patients with Moderate-to-Severe Pruritus

First NDA submission for Company’s lead program, KORSUVA™ Injection –NDA submission includes request for Priority Review under Breakthrough Therapy Designation...

error: Content is protected !!